Details

Autor(en) / Beteiligte

• Kato, Hideo
• Hagihara, Mao
• Yokoyama, Yuki
• Suematsu, Hiroyuki
• Asai, Nobuhiro
• Koizumi, Yusuke
• Yamagishi, Yuka
• Mikamo, Hiroshige

Titel

Comparison of the in Vivo Activities of Garenoxacin and Levofloxacin in a Murine Model of Pneumonia by Mixed-Infection with Streptococcus pneumoniae and Parvimonas micra

Ist Teil von

• Japanese Journal of Infectious Diseases, 2019, Vol.72(6), pp.407-412

Ort / Verlag

Japan: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Community-acquired pneumonia (CAP) can involve mixed-species bacterial infection. However, few studies have investigated antimicrobial efficacy in the treatment of mixed species infections. This study aimed to compare the in vivo antimicrobial activity of garenoxacin (GRNX) and levofloxacin (LVFX) against Streptococcus pneumoniae and Parvimonas micra in a murine model of mixed species bacterial pneumonia. S. pneumoniae D-6888 and P. micra No. 242 were used in this study. Antimicrobial activity toward each isolate was calculated as the change in bacterial count in the lungs (Δlog10 CFU/mL) of mice after 24 h of treatment compared with the count in pretreated animals (0 h). The MICs of GRNX and LVFX against S. pneumoniae D-6888 were 0.06 and 0.5 mg/L and the MICs against P. micra No. 242 were 0.03 and 0.12 mg/L, respectively. In a murine pneumonia mixed-infection model, GRNX showed significantly higher in vivo antimicrobial activity against S. pneumoniae than LVFX (GRNX; －2.02 ± 0.99 log10 CFU/mL vs. LVFX; －0.97 ± 0.61 log10 CFU/mL, p = 0.0188). GRNX displayed about 2-fold more potent activity against P. micra than LVFX (GRNX; －1.12 ± 0.56 log10 CFU/mL vs. LVFX; －0.61 ± 0.43 log10 CFU/mL, p = 0.1029). These results suggest that GRNX is preferable for the treatment of mixed species bacterial CAP.